NEW ORLEANS (WVUE) - If you have trouble affording prescription drugs, some independent pharmacists say that so-called ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

Sales of blood cancer drug Revlimid, which now has generic competition, dropped 11% to $1.41 billion in the quarter, but ...

On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...

Legacy Portfolio revenues were primarily driven by higher demand for Eliquis, partially offset by a decline in demand for Sprycel due to generic erosion. Eliquis sales reached $3 billion from $2. ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

The biopharma industry is on an upward trajectory, driven by groundbreaking advances in treatment options and a rising demand ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...

Bristol Myers Squibb exceeded third-quarter profit expectations with $3.7 billion earnings, due to strong sales in established and new drugs. Revenue climbed 8%, hitting $11.89 billion. However, the ...